Cutaneous T-cell Lymphoma Clinical Trial
Official title:
A Multicenter, Open-label, Randomized, Phase I/II Study Evaluating the Safety and Efficacy of Low-dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) Combined With Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides (MF)
The purpose of this study is to determine if vorinostat combined with low-dose total skin
electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over
low-dose TSEBT alone in participants with mycosis fungoides (MF)
Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.
Vorinostat is a histone deacetylase inhibitor (HDAC) that is FDA-approved for treatment of
mycosis fungoides (MF), and has shown activity as a radiation-sensitizer in preclinical
studies. Treatment of various cell lines [glioblastoma multiforme (GBM), non-small cell lung
cancer (NSCLC), melanoma] has shown that pretreatment with vorinostat had a significant
effect on radiation kill. This effect is believed to be secondary to multiple mechanisms that
may involve antiproliferative growth inhibition and effects on DNA repair after exposure to
radiation. A histone deacetylase inhibitor such as vorinostat may act as a radiosensitizer by
modulating the expression of single- and double-strand DNA repair proteins such as KU67,
KU86, H2AX, and Rad50. These DNA repair proteins are enzymes of that repair radiation-induced
damage. The decrease in these DNA repair enzymes is thought to be the key mechanism of
sensitization. Down-regulation of several key proteins involved in the nonhomologous end
joining pathway is thought to generate a G2/M checkpoint blockade. Vorinostat may also cause
an "open chromatin" structure increasing the effect of radiation damage to DNA. This is
exemplified by the finding that there is a prolonged H2AX phosphorylation and H2AX foci
formation. The mechanism producing this prolongation of H2AX foci is thought to contribute to
the damage, and thus killing effect of the radiation.
In the pivotal phase 2 trial of vorinostat, an overall response rate of nearly 30% was
reported. The median time to progression was 4.9 months overall, and 9.8 months for MF stage
IIB or higher responders. Through hyperacetylation of both histone and non-histone proteins,
vorinostat is felt to exert its anti-tumor activity via several mechanisms, including cell
cycle arrest, induction of apoptosis, reactive oxygen species generation, cell
differentiation, and angiogenesis inhibition. Importantly, a number of pre-clinical studies
have reported on the potential of vorinostat to enhance radiosensitivity of several different
human tumor cell lines. The rational for clinical trial investigating combination of
vorinostat and TSEBT not only comes from their underlying mechanism for potential synergy as
suggested by prior in-vitro studies but also due to general therapeutic advantage derived
from their non-overlapping toxicities.
Recent results from a phase 1 dose-escalation trial combining palliative pelvic radiation (30
Gy in 3 Gy fractions over 2 weeks) and vorinostat in study participants with
histologically-confirmed intrapelvic gastrointestinal carcinoma. Sixteen participants were
enrolled into cohorts of escalating vorinostat dose (100 mg, 200 mg, 300 mg, and 400 mg
daily). The most common adverse events were grade 1 and 2, among which fatigue and
gastrointestinal events were most common. Grade 3 adverse events included fatigue (n = 5),
hyponatremia (n = 1), hypokalemia (n = 1), and acneiform rash (n = 1). Of these, treatment
related grade 3 events [ie, dose limiting toxicities (DLT)] were observed in 1 of 6
participants at vorinostat 300 mg daily (fatigue and anorexia), and in 2 of 6 participants at
the 400 mg daily dose. As a result, the maximum tolerated dose of vorinostat in combination
with palliative radiotherapy was determined to be 300mg daily. The study concluded that
vorinostat can be safely combined with short term palliative radiotherapy. It should be noted
that the adverse events observed in the combination trial overlap with the toxicity profile
of vorinostat listed in the package insert.
Anecdotal experience in a patient who was failing standard course of TSEBT is relevant and is
described here. This patient's skin lesions were progressing towards the latter half of his
TSEBT course, thus, vorinostat was initiated and overlapped with TSEBT in the last 2 weeks.
The patient tolerated the combination well without any worsening skin reactions and his skin
lesions cleared completely. At one year follow-up, his skin is still in complete remission.
Another patient received a combination of romidepsin, another (HDAC) inhibitor, and low-dose
(12 Gy) TSEBT. He had CR after the addition of TSEBT, while his skin lesions were stable on
romidepsin alone.
Based on preclinical, early clinical data and anecdotal experience, it is anticipated that
vorinostat in combination with TSEBT can be administered safely and will be tolerated in
participants with MF. In addition, within the recognized limits of a phase 1-2 clinical
trial, this study may provide an assessment of the anti-tumor activity of vorinostat in
combination with TSEBT in participants with MF and thus allow us to evaluate the
radiation-enhancing potential of vorinostat.
This study is a multicenter phase 1-2, randomized, 2-arm trail exploring the efficacy of
TSEBT 12 Gy alone vs TSEBT 12 Gy + vorinostat. 12 Gy was selected for this study because it
is effective as a rapid debulking agent (with overall response rates of near 100% in the
retrospective study and ongoing clinical trial) and can be administered conveniently over 3
weeks. Because of the diminished clinical CR rates associated with TSEBT doses < 30 Gy, it is
proposed that combining TSEBT 12 Gy with vorinostat will lead to significantly higher
complete response (CR) rates, longer time-to-progression (TTP), and improved quality of life
as compared to TSEBT 12 Gy alone. Based on the retrospective study and preliminary experience
in the ongoing 12 Gy TSEBT trial, it is hypothesized that 12 Gy is an adequate dose to
achieve clinically meaningful outcomes and that the vorinostat may enhance its clinical
efficacy while minimizing radiation-associated toxicities due to the shortened treatment
duration.
Participants are stratified by MF stage as follows.
- Stage IB: ~10 % skin involvement, with up to 1000/mm3 clone+ Sezary cells in blood.
- Stage IIA: Up to 10 % skin involvement, with up to 1000/mm3 clone+ Sezary cells in blood
and clinically abnormal peripheral lymph nodes.
- Stage IIB: One or more tumors 1 cm in diameter, with up to 1000/mm3 clone+ Sezary cells
in blood and clinically abnormal peripheral lymph nodes.
- Stage IIIB: Skin erythema >80 % body surface area, with up to 1000/mm3 clone+ Sezary
cells in blood and clinically abnormal peripheral lymph nodes.
For detailed staging information, see References: Olsen E, et al. Blood. 2007;110:1713-1722.
PMID: 17540844
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT02881749 -
Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
|
Phase 2 | |
Completed |
NCT00744991 -
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
|
Phase 2 | |
Completed |
NCT00099593 -
Immunization Against Tumor Cells in Sezary Syndrome
|
Phase 2 | |
Completed |
NCT02593045 -
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
|
Phase 1 | |
Recruiting |
NCT00779896 -
Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT00177268 -
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
|
||
Completed |
NCT01728805 -
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
|
Phase 3 | |
Withdrawn |
NCT00969085 -
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
|
Phase 2 | |
Completed |
NCT00412997 -
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
|
Phase 1 | |
Completed |
NCT00254332 -
Effect of Denileukin Diftitox on Immune System in CTCL Patients
|
N/A | |
Recruiting |
NCT04296786 -
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study
|
Phase 2 | |
Recruiting |
NCT06285370 -
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
|
Phase 4 | |
Completed |
NCT00071084 -
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
|
Phase 2 | |
Completed |
NCT00896493 -
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
|
Phase 2 | |
Terminated |
NCT00699296 -
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
|
Phase 2 | |
Completed |
NCT02676778 -
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02061449 -
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
|
Phase 1 | |
Completed |
NCT01134341 -
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
|
Phase 1 |